Skip to main content

Basilea Pharmaceutica (BSLN): Renewed Focus on Anti-Infectives

LONDON, UK / ACCESSWIRE / May 5, 2022 / In February, Basilea announced a strategic refocusing on its core anti-infective business and is exploring strategic options for its oncology assets. Strong FY21 results were driven by key anti-infective assets Cresemba and Zevtera, which collectively contributed CHF131.4m to Basilea's revenue (up 18% y-o-y). Global Cresemba sales were US$324m in FY21, resulting in significantly increased royalty and milestone payments. Management envisages sustainable profitability and positive operating cash flow from 2023. Top-line data from the key ERADICATE study of Zevtera in bloodstream infections is expected in mid-2022. If positive, this would enable an NDA submission, paving the way to the US antibiotics market. In oncology, potential value uplift could come from positive readouts (expected in H122) from lead asset derazantinib in trials for iCCA (FIDES-01) and gastric cancer (FIDES-03).

Our rNPV model suggests a fair value of CHF847.7m or CHF71.6/share (previously CHF106/share). We value the oncology assets at CHF14.8/share, excluding any valuation for potential strategic actions. We have revisited our Cresemba and Zevtera milestone payment assumptions and are now taking a more conservative view. We roll our model forward, with FY21 net debt of CHF69.3m.

Click here to view the full report or here to sign up to receive research as it is published.

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Soo Romanoff +44 (0)20 3077 5700

Dr Harry Shrives +44 (0)20 3077 5700

Learn more at and connect with Edison on:




SOURCE: Edison Investment Research Limited

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.